Akero Therapeutics

FGF21 analogue, metabolic disease, MASH

modulatingbiologic

akerotx.com·San Francisco, California, United States·Founded 2017·Acquired·$6.1B total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-7ZR4

Summary · Eternal Search editorial

Akero Therapeutics FGF21 analogue, metabolic disease, MASH

Akero is a clinical-stage company developing transformational treatments for serious metabolic diseases. Its pipeline is anchored by efruxifermin (EFX), a novel FGF21 analogue designed to treat MASH by harnessing the natural biology of FGF21. The company states that Novo Nordisk acquired Akero in 2025 to unlock the full potential of efruxifermin and reach more patients living with MASH.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite57

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Akero Therapeutics — Near-term readout · Upper middle. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Modifiers: +5 depth (3 programs at…

Source: Deterministic

At a glance

Webakerotx.com

HQSan Francisco, California, United States

Founded2017

StageAcquired

Headcount32

Publications

19 on file

012026Efruxifermin improved digital pathology and noninvasive fibrosis measures in participants with MASH and advanced fibrosis or compensated cirrhosis: analysis of the HARMONY and SYMMETRY phase 2b trials—→022026Study design, rationale, and baseline characteristics of the SYNCHRONY Real-World Trial: a phase 3 trial evaluating efruxifermin in participants with MASLD or MASH—→032026FGF21 receptor agonism reverses steatosis by directing FFA to mitochondria and increasing their oxidation, without raising mtROS—→042026Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH—→052025Efruxifermin reduced fibrosis and septa area by quantitive digital pathology in participants with compensated cirrhosis due to MASH: Results from the 96-week, placebo-controlled, Phase 2B SYMMETRY trial—→062025Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial—→072025Efruxifermin improved fibrosis due to MASH in participants with F2/F3 fibrosis or compensated cirrhosis due to MASH: results of two 96-week, randomized, double-blind, placebo-controlled, phase 2b trials—→082025AI-powered histology analysis of HARMONY reveals efruxifermin-driven changes in the liver microarchitecture in F2/F3 MASH—→092025Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. Reply.The New England journal of medicine→102025Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.Lancet (London, England)→112025Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.The New England journal of medicine→122025Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association→132025Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White Adults.Journal of clinical pharmacology→142024FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond.Journal of hepatology→152023Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin.Journal of pharmaceutical and biomedical analysis→162023Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.The lancet. Gastroenterology & hepatology→172023A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.JHEP reports : innovation in hepatology→182022Tenofovir alafenamide fumarate.Antiviral therapy→192021Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.Nature medicine→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Akero Therapeutics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.